Top Markets
#1 Islamic Coin Islamic Coin +151.57%
#2 Fake World Assets Fake World Assets +29.88%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.39%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.38%
#5 Palladium Network Palladium Network +12.71%
#6 clBTC clBTC +12.14%
#7 Akedo Akedo +11.89%
#8 TENDIES TENDIES +10.53%
#9 Pons Pons +10.38%
#10 Pieverse Pieverse +8.97%
Coin of the day
Islamic Coin Islamic Coin
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Cyxone AB (publ) Cyxone AB (publ)

Cyxone AB (publ)

CYXO
Rang in aandelen #40403
Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing... Cyxone AB (publ) is a clinical-stage biotechnology firm focused on developing innovative, disease-modifying therapies. Its primary therapeutic targets include rheumatoid arthritis, multiple sclerosis, and acute respiratory illnesses caused by viruses. The company's pipeline features Rabeximod, currently in Phase II clinical trials for both rheumatoid arthritis and COVID-19. Additionally, T20K, a drug candidate for multiple sclerosis, is undergoing Phase 1 evaluation. Established in 2015, the company is headquartered in Malmö, Sweden.
Aandeelprijs
$0.00162013
Laatst gesynchroniseerd: 2025-01-03
Marktkapitalisatie
$156.25K
Verandering (1 dag)
0.36%
Verandering (1 jaar)
0.00%
Land
SE
Handel Cyxone AB (publ) (CYXO)

Categorie

Healthcare
Winst voor Cyxone AB (publ) (CYXO)
Winst in Jun 2024 TTM: $-2.04M
Volgens de meest recente financiële verslagen van Cyxone AB (publ) bedraagt de huidige winst van het bedrijf $-2.04M. In 2022 behaalde het bedrijf een winst van $-4.07M, een stijging ten opzichte van de winst van 2021, die $-4.98M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Cyxone AB (publ) van 2015 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-2.04M -10.32%
2023 $-2.28M -44.05%
2022 $-4.07M -18.14%
2021 $-4.98M -16.09%
2020 $-5.93M 57.40%
2019 $-3.77M 118.05%
2018 $-1.73M 60.09%
2017 $-1.08M 135.58%
2016 $-458.07K -2,484.88%
2015 $19.21K 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -258,252.37%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -95,564.36%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -147,199.10%
BE